SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg10/17/2005 2:45:01 PM
  Read Replies (1) of 1826
 
Lannett Gets FDA OK for Generic Salagen
Associated Press
10.17.2005, 10:36 AM

Lannett Co., a maker of generic drugs, said Monday it received Food and Drug Administration approval to market a generic version of MGI Pharma's Salagen.

The company received approval to market pilocarpine hydrochloride, the active ingredient in Salagen, a medication used to treat dry mouth resulting from radiation treatment of head and neck cancers.

MGI Pharma reported Salagen sales $29.3 million in 2004, but suspended promotion of the drug after generic drug makers began marketing their version this year.

Lannett shares rose 15 cents, or 3.2 percent, to $4.90 in morning trading on the American Stock Exchange.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News